remission maintenance with histamine dihydrochloride (hdc)/il-2 therapy in aml
Published 7 years ago • 280 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
6:18
biomarkers for acute myeloid leukemia (aml) – lessons from il-2 immunotherapy with hdc
-
1:50
histamine dihydrochloride and il-2 for aml: impacts for relapse risk and survival
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors
-
2:32
mdm2 inhibition in aml: trial updates
-
2:19
maintaining remission in aml and improving long-term survival in patients who do not receive hsct
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
1:27
the role of menin inhibitors in the treatment of hr-mds and aml
-
2:15
extending remission in patients with aml who become eligible for allosct following targeted therapy
-
18:02
management of haematological patients requiring emergency chemotherapy in the intensive care unit.
-
4:19
blinatumomab to achieve remission and consolidation with haplosct for pediatric all
-
20:44
update: new drugs for aml
-
0:47
the potential of mdm2 inhibitors in the treatment of mpn
-
1:19
new treatments for aml
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
3:52
maintenance therapy with revumenib following allosct in kmt2ar and npm1-mutated acute leukemias
-
3:46
current and emerging treatment options for lr-mds-associated anemia following esa failure
-
8:40
investigating pp2a-based therapeutic strategies for kmt2a-rearranged acute leukemia
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
1:26
effective immunomodulation with pomalidomide during induction tst for aml and mds